Risk of cutaneous adverse events with febuxostat treatment in patients with skin reaction to allopurinol. A retrospective, hospital-based study of 101 patients with consecutive allopurinol and febuxostat treatment - 03/05/16
, Gérard Chalès d, Tristan Pascart e, René-Marc Flipo e, Hang Korng Ea a, b, c, Jean-Claude Roujeau f, Aurélie Delayen g, Pierre Clerson gBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 4 |
| Iconographies | 0 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Objective |
To investigate the cutaneous tolerance of febuxostat in gouty patients with skin intolerance to allopurinol.
Methods |
We identified all gouty patients who had sequentially received allopurinol and febuxostat in the rheumatology departments of 4 university hospitals in France and collected data from hospital files using a predefined protocol. Patients who had not visited the prescribing physician during at least 2 months after febuxostat prescription were excluded. The odds ratio (OR) for skin reaction to febuxostat in patients with a cutaneous reaction to allopurinol versus no reaction was calculated. For estimating the 95% confidence interval (95% CI), we used the usual Wald method and a bootstrap method.
Results |
In total, 113 gouty patients had sequentially received allopurinol and febuxostat; 12 did not visit the prescribing physician after febuxostat prescription and were excluded. Among 101 patients (86 males, mean age 61±13.9 years), 2/22 (9.1%) with a history of cutaneous reactions to allopurinol showed skin reactions to febuxostat. Two of 79 patients (2.5%) without a skin reaction to allopurinol showed skin intolerance to febuxostat. The ORs were not statistically significant with the usual Wald method (3.85 [95% CI 0.51–29.04]) or bootstrap method (3.86 [95% CI 0.80–18.74]).
Conclusion |
The risk of skin reaction with febuxostat seems moderately increased in patients with a history of cutaneous adverse events with allopurinol. This moderate increase does not support the cross-reactivity of the two drugs.
Le texte complet de cet article est disponible en PDF.Keywords : Allopurinol, Febuxostat, Gout, Cross-reactivity, Skin reaction, Severe cutaneous adverse reaction (SCAR)
Plan
Vol 83 - N° 3
P. 314-317 - mai 2016 Retour au numéro
Article précédent
- Reduced incidence of Type 1 diabetes and Type 2 diabetes in systemic sclerosis: A nationwide cohort study
- Chia-Chun Tseng, Shun-Jen Chang, Wen-Chan Tsai, Tsan-Teng Ou, Cheng-Chin Wu, Wan-Yu Sung, Ming-Chia Hsieh, Jeng-Hsien Yen
- A novel method for a fast diagnosis of septic arthritis using mid infrared and deported spectroscopy
- Jean-David Albert, Valérie Monbet, Anne Jolivet-Gougeon, Nadia Fatih, Maëna Le Corvec, Malik Seck, Frédéric Charpentier, Guillaume Coiffier, Catherine Boussard-Pledel, Bruno Bureau, Pascal Guggenbuhl, Olivier Loréal
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?